BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-658@pharmaconomics
DTSTAMP:20260707T034232Z
DTSTART;VALUE=DATE:20251211
DTEND;VALUE=DATE:20251212
SUMMARY:IBRX AdCom — ANKTIVA
DESCRIPTION:An FDA advisory committee reviews ANKTIVA for non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) around Dec 11\, 2025. The panel's public vote often front-runs the agency's final verdict — and the share price.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000018/ibrx-20262188xkexhibit991.htm\n\nTrack it: https://www.pharmaconomics.com/e/658
URL:https://www.pharmaconomics.com/e/658
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:IBRX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR